A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

NCT06371157 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

469

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: AK104
DRUG: Lenvatinib
PROCEDURE: TACE
OTHER: Placebo for AK104
OTHER: Placebo for Lenvatinib

Sponsor

Akeso